(Reuters) - Celgene Corp said on Tuesday it would buy Receptos Inc for $7.2 billion in a move that will give the U.S. biotechnology company a potential multibillion-dollar drug in late stage ...
Shares of Celgene, a biotech blue-chip stock that generates most of its revenue from the development of oncology, inflammation, and immunology drugs, dipped 11% in November, based on data from S&P ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results